Life Sciences

Our team in Japan prides itself on its longstanding local relationships, forged from the many years spent working to serve the interests of a diverse and continuously expanding client base. As one of the first international firms to open in Japan, Jones Day’s life sciences practice was instrumental in the development of our office in Tokyo and was a key player in the mergers of major domestic pharmaceutical companies that reshaped the Japanese market, including Sumitomo Pharmaceutical’s merger with Dainippon Pharmaceuticals.
 
Our team of Japanese bengoshi and foreign attorneys - each of whom possessing more than 20 years of experience in their area of practice - advise leading domestic and international life sciences companies on the full scope of issues affecting them, including:

• major domestic and cross-border acquisitions and joint ventures;
• co-development, licensing, distribution and other strategic arrangements;
• high-stakes litigation, arbitration and other dispute resolution involving, among others, Hatch-Waxman disputes and patent infringement;
• antitrust matters;
• data privacy, including the international transmission of patient data;
• investigations involving FCPA and Japan’s Pharmaceuticals and Medical Devices Act, among others;
• market entry and clinical trials in Japan.
 
The Tokyo team forms a key part of our deeply integrated global practice, which advises the world’s premier life sciences companies across offices throughout the Asia-Pacific, Europe and US.